GoodRx (GDRX) announced that it is providing access to self-pay pricing for Novo Nordisk’s (NVO) Ozempic pill, helping eligible patients with type 2 diabetes obtain the medication for as low as $149 per month at pharmacies nationwide.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx Names Thomas Chan Chief Accounting Officer
- GoodRx offers access to Wegovy HD at $399 per month self-pay price
- GoodRx expands access to Eli Lilly’s new oral GLP-1 Foundayo
- GoodRx Reshapes Board After Director Resignation and Reclassification
- GoodRx Chief Accounting Officer Resigns for New Opportunity